Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.46 USD
Change Today +0.03 / 2.10%
Volume 285.5K
NAVB On Other Exchanges
NAVB is not on other exchanges.
As of 3:38 PM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

navidea biopharmaceuticals i (NAVB) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/24/14 - $2.02
52 Week Low
11/12/14 - $0.97
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

navidea biopharmaceuticals i (NAVB) Related Businessweek News

View More BusinessWeek News

navidea biopharmaceuticals i (NAVB) Details

Navidea Biopharmaceuticals, Inc., a precision medicine company, focuses on the development and commercialization of precision diagnostics, therapeutics, and radiopharmaceutical agents. The company offers Lymphoseek Injection, a receptor-targeted small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients; and Manocept platform to target the CD206 mannose receptor expressed on macrophages. Its development programs include NAV4694, an Fluorine-18 radiolabeled positron emission tomography imaging agent, which is used as an aid in the diagnosis of patients with signs or symptoms of Alzheimer’s disease and mild cognitive impairment; and NAV5001, an Iodine-123 radiolabeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson’s disease and other movement disorders with potential use as a diagnostic aid in dementia. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California, AstraZeneca AB, and Alseres Pharmaceuticals, Inc. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

46 Employees
Last Reported Date: 03/16/15
Founded in 1983

navidea biopharmaceuticals i (NAVB) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $82.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $260.0K
Executive Vice President and Chief Business O...
Total Annual Compensation: $314.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $300.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $279.1K
Compensation as of Fiscal Year 2014.

navidea biopharmaceuticals i (NAVB) Key Developments

Navidea Biopharmaceuticals, Inc Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 02:00 PM

Navidea Biopharmaceuticals, Inc Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 02:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Ricardo J. Gonzalez, Chief Executive Officer, President and Director.

Navidea Biopharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Its Lymphoseek Revenue Guidance for 2015 and Cash Flow Results for the First Quarter of 2016

Navidea Biopharmaceuticals Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the period, the company has posted total revenue of $2,108,456 against $751,804 a year ago. Loss from operations was $7,816,057 against $8,579,043 a year ago. Net loss was $7,291,225 against $11,740,553 a year ago. Net loss attributable to common stockholders was $7,337,125 or $0.05 basic and diluted against $11,740,553 or $0.08 basic and diluted a year ago. First quarter product revenues recognized from the sale of Lymphoseek were $1.84 million compared to $1.46 million for the fourth quarter of last year and $627,000 in the first quarter of last year. This represents a sequential quarter-on-quarter growth of 26% and year-over-year growth of approximately 200%. Based on progress, the company reaffirmed its $10 to $12 million Lymphoseek revenue guidance for 2015. Additionally, margins on product sales are expected to approach and possibly exceed 80% in the coming quarters and expectation of achieving cash-flow breakeven from operations during the first quarter of 2016.

Navidea Biopharmaceuticals, Inc. Secures $60 Million Loan with CRG

Navidea Biopharmaceuticals Inc. announced that it has entered into a term loan with CRG (formerly Capital Royalty L.P.), which provides for an initial funding of $50 million at closing. The majority of the funds provided by CRG will be used by Navidea to retire its debt from Oxford Finance LLC in its entirety. After repayment of the Oxford debt, this transaction will provide a net amount of $18 million in capital to Navidea. Proceeds will be used to support the growth of the Company’s Manocept™ technology, initially as a FDA-approved cancer imaging agent, Lymphoseek® (technetium Tc 99m tilmanocept) injection, and for general operating purposes.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NAVB:US $1.46 USD +0.03

NAVB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $2.08 USD -0.035
Curis Inc $3.51 USD +0.005
Exact Sciences Corp $27.38 USD +0.31
View Industry Companies

Industry Analysis


Industry Average

Valuation NAVB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NAVIDEA BIOPHARMACEUTICALS I, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at